In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CRO ShangPharma nets $44.7mm in IPO

Executive Summary

Chinese CRO ShangPharma Corp. has netted $44.7mm through its initial public offering of 3.2mm American Depositary Shares at $15 each, on the lower end of the company's $14.50-16.50 range. Each ADS represents 18 ordinary shares. Existing shareholders have also sold 2.6mm ADSs.
Deal Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies